C12N 5/0037
Serum-free medium, which may still contain naturally-sourced components
Official title: {Serum-free medium, which may still contain naturally-sourced components}
C12N5/0037 (Serum-free medium, which may still contain naturally-sourced components) appears on 228 US grants and 325 published applications in this corpus.
Search patents in C12N- Granted patents
- 228
- Published applications
- 325
- Assignees
- 218
- Inventors
- 698
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 2 | 0 |
| 1985 | 2 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 2 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 4 | 0 |
| 1992 | 3 | 0 |
| 1993 | 3 | 0 |
| 1994 | 3 | 0 |
| 1995 | 0 | 0 |
| 1996 | 3 | 0 |
| 1997 | 5 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 3 | 0 |
| 2002 | 0 | 6 |
| 2003 | 1 | 3 |
| 2004 | 2 | 5 |
| 2005 | 2 | 2 |
| 2006 | 0 | 9 |
| 2007 | 1 | 4 |
| 2008 | 1 | 8 |
| 2009 | 3 | 9 |
| 2010 | 2 | 9 |
| 2011 | 6 | 15 |
| 2012 | 10 | 9 |
| 2013 | 8 | 13 |
| 2014 | 12 | 16 |
| 2015 | 15 | 18 |
| 2016 | 14 | 20 |
| 2017 | 5 | 24 |
| 2018 | 10 | 13 |
| 2019 | 14 | 26 |
| 2020 | 11 | 21 |
| 2021 | 9 | 19 |
| 2022 | 12 | 19 |
| 2023 | 15 | 18 |
| 2024 | 11 | 17 |
| 2025 | 16 | 18 |
| 2026 | 8 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for increasing mannose content of recombinant proteins21 Jul 2026US 12,686,880 B2Amgen Inc.
- Media for culturing naive human pluripotent stem cells14 Jul 2026US 12,680,083 B2Yeda Research and Development Co. Ltd.
- Gamma delta T cells derived from induced pluripotent stem cells, and production method therefor17 Mar 2026US 12,576,149 B2National University Corporation Kobe University
- Suspension mode seed train development for adherent cells17 Mar 2026US 12,577,540 B2Sarepta Therapeutics, Inc.
- Recombinant humanized collagen type III alpha-1, and expression vector and use thereof10 Mar 2026US 12,570,723 B2Shandong D-Nutrimec Biomedical Co., Ltd.
- Tumor storage and cell culture compositions13 Aug 2026US 2026/0234568 A1Iovance Biotherapeutics, Inc.
- Basal medium composition for animal cell culture23 Jul 2026US 2026/0209692 A1IntegriCulture Inc.
- Uterine treatment composition, uterine environment-improving agent, implantation aid, embryo transplantation liquid, sperm transplantation liquid, and implantation rate-improving agent18 Jun 2026US 2026/0166086 A1Hiroshima University
- Preparation method for adenovirus p53-loaded dendritic cell vaccine14 May 2026US 2026/0130977 A1Scinosen (Shenzhen) Gene Industry Development Co. Ltd.
- Methods for treating myeloid malignancies20 Nov 2025US 2025/0352570 A1GammaDelta Therapeutics Ltd
Most cited
By later US patents
- Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins500US 5,122,469 AGenentech, Inc. · 1992
- Serum-free cell culture medium and process for making same430US 4,560,655 AImmunex Corporation · 1985
- Cell culture medium for enhanced cell growth, culture longevity, and product expression160US 6,048,728 AChiron Corporation · 2000
- Fed-batch cell culture methods using non-animal-based hydrolysates79US 8,093,045 B2Abbott Laboratories · 2012
- Chemically defined medium for cultured mammalian cells58US 6,900,056 B2Centocor, Inc. · 2005